Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Exciting Revelations from the NACFC 2018 Poster Sessions, Part 2 AbbVie Takes Sole Control of Potential CF Therapies Developed with Galapagos Exciting Revelations from the NACFC 2018 Poster Sessions, Part 2 Nov 05, 2018 09:00 am | Tré LaRosa Second in a series. Read part one. The poster sessions at the North American Cystic Fibrosis Conference (NACFC) in Denver last month included many interesting branches of the wonderful world of CF research. In this column, I’ll continue a series with short overviews of interesting posters from each topic. This is not intended to be […] The post Exciting Revelations from the NACFC 2018 Poster Sessions, Part 2 appeared first on Cystic Fibrosis News Today. Read More AbbVie Takes Sole Control of Potential CF Therapies Developed with Galapagos Nov 05, 2018 07:00 am | Vijaya Iyer Galapagos and AbbVie agreed that AbbVie will now have full control of the cystic fibrosis (CF) drug discovery portfolio the two companies have developed together. This means that the exclusive global rights to the investigational therapeutic candidates for CF will be held by AbbVie alone. This decision comes after months of discussions between the two companies, which entered […] The post AbbVie Takes Sole Control of Potential CF Therapies Developed with Galapagosappeared first on Cystic Fibrosis News Today. Read More   Recent News Symkevi Approved in EU for CF Patients with Two F508del Mutations, or One Plus a Minimal Function Mutation Exciting Revelations from the NACFC 2018 Poster Sessions, Part 1 Vertex Announces Plans for Symdeko, Hopes for Triple Combos Now in Pivotal Trials Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014 Why Are Our Doctors Not Discussing Herbal Supplements with Us?